Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model

A magnetic resonance imaging study

Yoji Tanaka, Hideto Ishii, Megumi Hiraoka, Naoyuki Miyasaka, Toshihiko Kuroiwa, Katherine A. Hajjar, Tsukasa Nagaoka, Timothy Q. Duong, Kikuo Ohno, Masayuki Yoshida

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Efficacy of recombinant annexin 2 (rAN II) in a rat model of embolic stroke was examined using a magnetic resonance imaging (MRI) and histology. The right middle cerebral artery of male Wistar rats was occluded by autologous clots under anesthesia. Four doses of rAN II (0.125, 0.25, 0.5 and 1.0 mg/kg, n = 10 for each group) or saline (1 ml/kg, n = 10) were administrated intravenously within 5 min before clot infusion. Serial changes in apparent diffusion coefficient (ADC) and relative blood flow (CBF) were measured with the use of MRI in half of the animals in each group. The remaining half of the animals in each group was evaluated for hemorrhage and final infarct size by histology at 48 h after embolization. At 3 h after embolization, lesion volumes with ADC were abnormality and CBF in the peripheral lesion was improved in groups treated with 0.25, 0.5 and 1.0 mg/kg, but not 0.125 mg/kg, of rAN II in comparison with the saline-treated group (P < 0.05). Histological analyses were consistent with MRI findings. More importantly, no hemorrhagic transformation was documented in rats treated with 0.125 and 0.25 mg/kg of rAN II, whereas it was observed at higher doses. We concluded that rAN II at 0.25 mg/kg significantly reduced infarct size and improved CBF without hemorrhagic complications. rAN II is a novel compound that has the potential to be a promising fibrinolytic agent to treat embolic stroke.

Original languageEnglish (US)
Pages (from-to)135-143
Number of pages9
JournalBrain Research
Volume1165
Issue number1
DOIs
StatePublished - Aug 24 2007
Externally publishedYes

Fingerprint

Annexins
Thrombolytic Therapy
Stroke
Magnetic Resonance Imaging
Histology
Fibrinolytic Agents
Middle Cerebral Artery
Wistar Rats
Anesthesia
Hemorrhage

Keywords

  • Annexin 2
  • Cerebral ischemia
  • Fibrinolysis
  • Magnetic resonance imaging

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Tanaka, Y., Ishii, H., Hiraoka, M., Miyasaka, N., Kuroiwa, T., Hajjar, K. A., ... Yoshida, M. (2007). Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model: A magnetic resonance imaging study. Brain Research, 1165(1), 135-143. https://doi.org/10.1016/j.brainres.2007.06.039

Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model : A magnetic resonance imaging study. / Tanaka, Yoji; Ishii, Hideto; Hiraoka, Megumi; Miyasaka, Naoyuki; Kuroiwa, Toshihiko; Hajjar, Katherine A.; Nagaoka, Tsukasa; Duong, Timothy Q.; Ohno, Kikuo; Yoshida, Masayuki.

In: Brain Research, Vol. 1165, No. 1, 24.08.2007, p. 135-143.

Research output: Contribution to journalArticle

Tanaka, Y, Ishii, H, Hiraoka, M, Miyasaka, N, Kuroiwa, T, Hajjar, KA, Nagaoka, T, Duong, TQ, Ohno, K & Yoshida, M 2007, 'Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model: A magnetic resonance imaging study', Brain Research, vol. 1165, no. 1, pp. 135-143. https://doi.org/10.1016/j.brainres.2007.06.039
Tanaka, Yoji ; Ishii, Hideto ; Hiraoka, Megumi ; Miyasaka, Naoyuki ; Kuroiwa, Toshihiko ; Hajjar, Katherine A. ; Nagaoka, Tsukasa ; Duong, Timothy Q. ; Ohno, Kikuo ; Yoshida, Masayuki. / Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model : A magnetic resonance imaging study. In: Brain Research. 2007 ; Vol. 1165, No. 1. pp. 135-143.
@article{7791d78023194ee5a1579fd36d424c67,
title = "Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model: A magnetic resonance imaging study",
abstract = "Efficacy of recombinant annexin 2 (rAN II) in a rat model of embolic stroke was examined using a magnetic resonance imaging (MRI) and histology. The right middle cerebral artery of male Wistar rats was occluded by autologous clots under anesthesia. Four doses of rAN II (0.125, 0.25, 0.5 and 1.0 mg/kg, n = 10 for each group) or saline (1 ml/kg, n = 10) were administrated intravenously within 5 min before clot infusion. Serial changes in apparent diffusion coefficient (ADC) and relative blood flow (CBF) were measured with the use of MRI in half of the animals in each group. The remaining half of the animals in each group was evaluated for hemorrhage and final infarct size by histology at 48 h after embolization. At 3 h after embolization, lesion volumes with ADC were abnormality and CBF in the peripheral lesion was improved in groups treated with 0.25, 0.5 and 1.0 mg/kg, but not 0.125 mg/kg, of rAN II in comparison with the saline-treated group (P < 0.05). Histological analyses were consistent with MRI findings. More importantly, no hemorrhagic transformation was documented in rats treated with 0.125 and 0.25 mg/kg of rAN II, whereas it was observed at higher doses. We concluded that rAN II at 0.25 mg/kg significantly reduced infarct size and improved CBF without hemorrhagic complications. rAN II is a novel compound that has the potential to be a promising fibrinolytic agent to treat embolic stroke.",
keywords = "Annexin 2, Cerebral ischemia, Fibrinolysis, Magnetic resonance imaging",
author = "Yoji Tanaka and Hideto Ishii and Megumi Hiraoka and Naoyuki Miyasaka and Toshihiko Kuroiwa and Hajjar, {Katherine A.} and Tsukasa Nagaoka and Duong, {Timothy Q.} and Kikuo Ohno and Masayuki Yoshida",
year = "2007",
month = "8",
day = "24",
doi = "10.1016/j.brainres.2007.06.039",
language = "English (US)",
volume = "1165",
pages = "135--143",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model

T2 - A magnetic resonance imaging study

AU - Tanaka, Yoji

AU - Ishii, Hideto

AU - Hiraoka, Megumi

AU - Miyasaka, Naoyuki

AU - Kuroiwa, Toshihiko

AU - Hajjar, Katherine A.

AU - Nagaoka, Tsukasa

AU - Duong, Timothy Q.

AU - Ohno, Kikuo

AU - Yoshida, Masayuki

PY - 2007/8/24

Y1 - 2007/8/24

N2 - Efficacy of recombinant annexin 2 (rAN II) in a rat model of embolic stroke was examined using a magnetic resonance imaging (MRI) and histology. The right middle cerebral artery of male Wistar rats was occluded by autologous clots under anesthesia. Four doses of rAN II (0.125, 0.25, 0.5 and 1.0 mg/kg, n = 10 for each group) or saline (1 ml/kg, n = 10) were administrated intravenously within 5 min before clot infusion. Serial changes in apparent diffusion coefficient (ADC) and relative blood flow (CBF) were measured with the use of MRI in half of the animals in each group. The remaining half of the animals in each group was evaluated for hemorrhage and final infarct size by histology at 48 h after embolization. At 3 h after embolization, lesion volumes with ADC were abnormality and CBF in the peripheral lesion was improved in groups treated with 0.25, 0.5 and 1.0 mg/kg, but not 0.125 mg/kg, of rAN II in comparison with the saline-treated group (P < 0.05). Histological analyses were consistent with MRI findings. More importantly, no hemorrhagic transformation was documented in rats treated with 0.125 and 0.25 mg/kg of rAN II, whereas it was observed at higher doses. We concluded that rAN II at 0.25 mg/kg significantly reduced infarct size and improved CBF without hemorrhagic complications. rAN II is a novel compound that has the potential to be a promising fibrinolytic agent to treat embolic stroke.

AB - Efficacy of recombinant annexin 2 (rAN II) in a rat model of embolic stroke was examined using a magnetic resonance imaging (MRI) and histology. The right middle cerebral artery of male Wistar rats was occluded by autologous clots under anesthesia. Four doses of rAN II (0.125, 0.25, 0.5 and 1.0 mg/kg, n = 10 for each group) or saline (1 ml/kg, n = 10) were administrated intravenously within 5 min before clot infusion. Serial changes in apparent diffusion coefficient (ADC) and relative blood flow (CBF) were measured with the use of MRI in half of the animals in each group. The remaining half of the animals in each group was evaluated for hemorrhage and final infarct size by histology at 48 h after embolization. At 3 h after embolization, lesion volumes with ADC were abnormality and CBF in the peripheral lesion was improved in groups treated with 0.25, 0.5 and 1.0 mg/kg, but not 0.125 mg/kg, of rAN II in comparison with the saline-treated group (P < 0.05). Histological analyses were consistent with MRI findings. More importantly, no hemorrhagic transformation was documented in rats treated with 0.125 and 0.25 mg/kg of rAN II, whereas it was observed at higher doses. We concluded that rAN II at 0.25 mg/kg significantly reduced infarct size and improved CBF without hemorrhagic complications. rAN II is a novel compound that has the potential to be a promising fibrinolytic agent to treat embolic stroke.

KW - Annexin 2

KW - Cerebral ischemia

KW - Fibrinolysis

KW - Magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=34547661654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547661654&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2007.06.039

DO - 10.1016/j.brainres.2007.06.039

M3 - Article

VL - 1165

SP - 135

EP - 143

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -